Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
SR

NASDAQ · SRZN

Surrozen, Inc.

Healthcare · Biotechnology

$29.02

Down-$0.02 (-0.07%)

Updated Nov 3, 2026, 2:29 AM

SID Score

6.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
201.6M
P/E ratio
-12.03
Dividend yield
0.00%
52-week range
$11.39 – $37.83
Volume
159.67K
Avg. volume
63.79K

Price performance · SRZN

SRZN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

SRZN closed at $29.02 after 21 trading sessions, down 0.38% for the selected period.

Last close
$29.02
Period change
-0.38%
Period low
$23.44
Period high
$30.35
Daily close
View OHLC price history
SRZN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$29.16$30.30$27.955$29.02159.67K
Oct 30, 2026$29.32$29.51$27.72$29.04231.86K
Oct 29, 2026$30.41$31.6075$29.10$29.46254.73K
Oct 28, 2026$29.45$30.535$29.45$30.35142.69K
Oct 27, 2026$27.38$30.35$27.28$29.53431.58K
Oct 26, 2026$25.23$27.75$24.97$27.28511.22K
Oct 23, 2026$25.11$26.79$24.56$25.481.55M
Oct 22, 2026$25.32$27.68$24.85$25.75137.03K
Oct 21, 2026$25.78$26.09$24.975$25.32118.84K
Oct 20, 2026$23.74$25.45$23.38$25.14323.89K
Oct 19, 2026$23.51$24.48$23.25$23.84295.93K
Oct 16, 2026$25.09$25.09$23.25$23.44269.02K
Oct 15, 2026$23.73$25.32$23.31$25.07363.82K
Oct 14, 2026$23.40$24.54$22.67$23.75631.59K
Oct 13, 2026$24.04$24.37$21.85$23.51868.79K
Oct 12, 2026$28.70$30.075$22.82$24.761.53M
Oct 9, 2026$27.86$30.97$27.53$29.69781.39K
Oct 8, 2026$25.00$28.85$23.54$27.97682.49K
Oct 7, 2026$25.81$26.21$25.08$25.145374.29K
Oct 6, 2026$29.26$29.26$26.1801$26.37603.82K
Oct 5, 2026$29.32$29.70$26.97$29.13439.18K

Latest SRZN news

The latest Smart Investors Daily articles mentioning SRZN.

Stock researchCompany · Overview

SRZN research

Overview

Company profile and research snapshot.

Company profile

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$38.50
Implied upside
—
Analysts
8
SRZN recent ratings
DateFirmRatingTarget
Sep 25, 2026HC Wainwright & Co.Buy—
Aug 20, 2026William BlairOutperform—
Aug 10, 2026HC Wainwright & Co.Buy—
May 7, 2026HC Wainwright & Co.Buy—
Apr 21, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million

Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the closing of the second and final tranche of its March 2025 private p

Yahoo · Oct 15, 2026

Top Biotech Stock: Guggenheim Names Surrozen as Best Pick

Investing.com -- Guggenheim Securities has identified Surrozen, Inc. as its top pick in the biotechnology sector, assigning a Buy rating with a price target of $42.00. The firm hosted management from Surrozen to discuss recent developments in retinal vascular disease treatments and the company's clinical pipeline.

Yahoo · Oct 2, 2026

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By